"By using a molecular diagnostic test to assess whether a breast tumor will respond to chemotherapy, we’re hoping to more precisely identify which patients can be adequately treated with hormonal therapy alone and which patients will truly benefit if chemotherapy is added to the treatment," said Joseph Sparano, MD, who directs the Breast Evaluation Center at the Montefiore-Einstein Cancer Center. "With better individualized treatment, we can spare women the side effects of chemotherapy where it is unnecessary."
Dr. Sparano is the lead investigator for the clinical trial, called TAILORx (an acronym for Trial Assigning Individualized Options for Treatment). The study, sponsored by the National Cancer Institute, will enroll about 10,000 women with breast cancer at more than 900 institutions throughout the United States and Canada.
Breast cancer is the most frequently diagnosed cancer in women, with an estimated 235,000 new cases of invasive breast cancer expected in the United States and Canada in 2006. Nearly 140,000 of these women will have estrogen receptor-positive breast cancer that has not yet spread to the lymph nodes.
The standard treatment is surgery to remove the tumor, plus radiation and hormonal therapy, which cures about 80 to 85 percent of patients. Adding chemotherapy can further reduce the risk of recurrence by about 25 percent, but it benefits only a small proportion of women.
Currently, most women with early-stage breast cancer are advised to undergo chemotherapy, yet it’s not clear that chemotherapy is worthwhile or even necessary in all these cases," Dr. Sparano said.
The researchers will use OncotypeDXTM, a modern diagnostic test developed by Genomic Health, Inc., in Redwood, Calif., in collaboration with the National Surgical Adjuvant Breast and Bowel Project, a network of cancer research professionals. The test identifies which of 21 specific genes are turned on or off in the tumor. This genetic assessment estimates a patient’s risk of recurrence more precisely than standard clinical characteristics, such as tumor size and grade. It also helps predict whether a patient will benefit from chemotherapy.
"This test yields what is called a recurrence score. For about 55 percent of women, the recurrence score is greater than 25 or less than 11. In these cases, the test clearly indicates the most effective therapy: a combination of chemotherapy and hormones for women with high scores, and hormones alone for women with low scores," Dr. Sparano said. "But about 45 percent of women receive scores that range from 11 to 25, where the treatment path is not so clear. Our study is designed to resolve this uncertainty."
Women participating in the TAILORx trial will be assigned to one of three groups depending on their recurrence score. If the score is more than 25, women will receive chemotherapy plus hormonal therapy, the current standard of care. If it is less than 11, they will receive hormonal therapy alone. If the recurrence score is between 11 and 25, women will be randomized to receive either hormonal therapy or hormonal therapy together with chemotherapy.
"With this trial, we’re taking a big leap forward in integrating modern molecular diagnostic testing into clinical decision-making in order to individualize cancer treatments," Dr. Sparano said.
Sharon Butler | EurekAlert!
Make way for the mini flying machines
21.03.2018 | American Chemical Society
New 4-D printer could reshape the world we live in
21.03.2018 | American Chemical Society
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
21.03.2018 | Life Sciences
21.03.2018 | Trade Fair News
20.03.2018 | Physics and Astronomy